Dr. Brentjens on Obstacles with CAR T-Cell Therapy in Hematologic Malignancies – OncLive
OncLive |
Dr. Brentjens on Obstacles with CAR T-Cell Therapy in Hematologic Malignancies
OncLive Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses challenges facing chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies. The FDA … |
